Cardiff Oncology Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(45,431) | $(41,441) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 404 | 398 |
| Stock-based compensation expense | 4,760 | 4,509 |
| Accretion of discounts on short-term investments, net | (598) | (921) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and unbilled receivable | (484) | 483 |
| Prepaid expenses and other current assets | (452) | 3,169 |
| Operating lease right-of-use assets | 539 | 543 |
| Other assets | 1,210 | 108 |
| Accounts payable and accrued liabilities | 2,985 | 2,831 |
| Operating lease liabilities | (626) | (566) |
| Net cash used in operating activities | (37,693) | (30,887) |
| Investing activities | ||
| Capital expenditures | (80) | (582) |
| Maturities of short-term investments | 27,106 | 86,552 |
| Purchases of short-term investments | (23,563) | (70,084) |
| Sales of short-term investments | 10,265 | 20,309 |
| Net cash provided by investing activities | 13,728 | 36,195 |
| Financing activities | ||
| Proceeds from sales of common stock, net of expenses of $3,286 and $0, respectively | 53,407 | — |
| Proceeds from exercise of options | 373 | — |
| Net cash provided by financing activities | 53,780 | — |
| Net change in cash and cash equivalents | 29,815 | 5,308 |
| Cash and cash equivalents—Beginning of period | 21,655 | 16,347 |
| Cash and cash equivalents—End of period | $51,470 | $21,655 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.